Last reviewed · How we verify

Artesunate-mefloquine+piperaquine

University of Oxford · Phase 3 active Small molecule

Artesunate-mefloquine+piperaquine is a Antimalarial combination therapy Small molecule drug developed by University of Oxford. It is currently in Phase 3 development for Uncomplicated malaria caused by Plasmodium falciparum, Malaria in areas with artemisinin or partner drug resistance.

This combination of three antimalarial agents works by disrupting parasite metabolism and preventing drug resistance through multiple complementary mechanisms of action.

This combination of three antimalarial agents works by disrupting parasite metabolism and preventing drug resistance through multiple complementary mechanisms of action. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria in areas with artemisinin or partner drug resistance.

At a glance

Generic nameArtesunate-mefloquine+piperaquine
SponsorUniversity of Oxford
Drug classAntimalarial combination therapy
TargetMultiple: artemisinin (heme-dependent mechanism), mefloquine (heme polymerization inhibition), piperaquine (heme polymerization inhibition)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Artesunate is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species. Mefloquine and piperaquine are quinoline-based antimalarials that inhibit heme polymerization and parasite protein synthesis. The triple combination leverages different mechanisms to prevent resistance development and provide synergistic efficacy against Plasmodium species.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate-mefloquine+piperaquine

What is Artesunate-mefloquine+piperaquine?

Artesunate-mefloquine+piperaquine is a Antimalarial combination therapy drug developed by University of Oxford, indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria in areas with artemisinin or partner drug resistance.

How does Artesunate-mefloquine+piperaquine work?

This combination of three antimalarial agents works by disrupting parasite metabolism and preventing drug resistance through multiple complementary mechanisms of action.

What is Artesunate-mefloquine+piperaquine used for?

Artesunate-mefloquine+piperaquine is indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria in areas with artemisinin or partner drug resistance.

Who makes Artesunate-mefloquine+piperaquine?

Artesunate-mefloquine+piperaquine is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What drug class is Artesunate-mefloquine+piperaquine in?

Artesunate-mefloquine+piperaquine belongs to the Antimalarial combination therapy class. See all Antimalarial combination therapy drugs at /class/antimalarial-combination-therapy.

What development phase is Artesunate-mefloquine+piperaquine in?

Artesunate-mefloquine+piperaquine is in Phase 3.

What are the side effects of Artesunate-mefloquine+piperaquine?

Common side effects of Artesunate-mefloquine+piperaquine include Nausea, Vomiting, Dizziness, Abdominal pain, Neuropsychiatric effects (mefloquine-related).

What does Artesunate-mefloquine+piperaquine target?

Artesunate-mefloquine+piperaquine targets Multiple: artemisinin (heme-dependent mechanism), mefloquine (heme polymerization inhibition), piperaquine (heme polymerization inhibition) and is a Antimalarial combination therapy.

Related